双蚁药业2025年营销工作总结暨2026年营销工作部署会议圆满召开

Core Insights - The meeting held by Shuangyi Pharmaceutical on January 4-5, 2026, focused on summarizing the marketing achievements of 2025 and outlining the strategic direction for 2026, emphasizing the theme "Diligent Learning and Practical Work for Breakthroughs, Unity and Execution for New Heights" [1][2] Group 1: 2025 Achievements - In 2025, Shuangyi Pharmaceutical achieved significant growth, with sales and cash recovery both increasing, with cash recovery up by 56% and sales up by 25% year-on-year [2] - The core product, Compound Cold Granules, saw steady sales growth, and the medical sector made breakthrough progress in market development [1][2] Group 2: 2026 Strategic Direction - Chairman Wang Bo expressed expectations for the marketing team to enhance professional capabilities and broaden development horizons, aiming to position the company among renowned pharmaceutical brands like Beijing Tongrentang and Yunnan Baiyao [2] - Vice President Liang Liyan outlined the 2026 marketing strategy, emphasizing a "Change and Stability" approach, maintaining core structures while adapting marketing goals and strategies to market changes [3] Group 3: Team Engagement and Best Practices - The meeting included presentations from various centers, summarizing 2025 achievements and discussing 2026 marketing plans, with a focus on ensuring effective implementation through interactive discussions [3][4] - An awards ceremony recognized outstanding individuals and teams from 2025, fostering a competitive spirit and encouraging collective effort towards achieving the company's goals [5]